As external innovation continues to be a critical part of portfolio strategy for the biggest BioPharma players, it drives the deals activity as companies race to license and acquire the assets that will give them market segment dominance. All indications are that 2018 will another mega-dealmaking year as big dollars have flowed forth for licensing and M&A deals in the first half of the year. Using Cortellis tools, our experts delve into these partnerships and M&As to provide attendees with valuable market insights:
Who has emerged early in the year as the biggest dealmakers
A breakdown of the top 3 biopharma licensing deals and the top 3 M&A deals
What therapeutic areas stand out, and why
A closer examination of the burgeoning Asia Pacific region where dealmakers are more active than ever
Preview of the biggest deals and outlook for Q3
Expert Speakers
Paul D'Souza, Pharmaceutical Industry Analyst at Clarivate Analytics
Paul has 11 years experience supporting pharmaceutical and consultancy clients through analyses of pharmaceutical drugs, M&A and licensing deals data, particularly Cortellis CDI
Paul currently analyses quarterly trends in pharmaceutical M&A and licensing activity
Donald Johnston, Senior Marketing Communication Director at Clarivate Analytics
Donald is senior marketing communication director at Clarivate Analytics
Don has worked with Clarivate’s Life Sciences solutions, particularly the BioWorld and BioWorld MedTech news services, for more than two decades
Event details
Date October 03, 2018
Time 10 AM EDT/ 3 PM BST
Who should attend
Professionals in business development and licensing, mergers and acquisitions
Marketing strategy professionals
Biopharma financial sector
Anyone with a need for monitoring the Biopharma deals landscape
What you will learn
After you attend this webinar, you will have learned this key information on BioPharma deals in the first half of 2018:
Details on the top 3 global BioPharma licensing deals
Specifics for the top 3 global BioPharma mergers/acquisitions
The key licensing and M&A deals in the Asia Pacific (APAC) region